Posted On: 11/11/2014 7:45:24 AM
Post# of 30064
" In addition to LymPro and our NuroPro Parkinson’s diagnostic, we are actively evaluating additional complementary late-stage neurology-focused diagnostic assets that would bolster our diagnostic division and make for a successful ‘spin-out’ while concurrently returning value to our shareholders."
(0)
(0)Scroll down for more posts ▼
